BlueRiver Acquisition in an 8-K said it had entered a non-redemption agreement with an investor who will hold onto 200,000 shares when the SPAC’s stockholders vote on a deadline extension proposal that would give BlueRiver until August to seal a deal. In return, the SPAC will give the non-redeeming investor 50,000 shares.
In a separate regulatory filing, BlueRiver said it has signed a non-binding letter of intent with a target in the medical technology sector.
Following a January 2021 IPO, the SPAC currently holds nearly $292 million in trust, according to the filing. Read more.
